The National Alliance of Healthcare Purchaser Coalitions releases resources for employers/health plan purchasers to offer insights on PBMs role in high prescription drug costs.
The National Alliance of Healthcare Purchaser Coalitions is pointing the finger at pharmacy benefit management or PBMs for high prescription drug costs. In a recent press release, the National Alliance encouraged employers to challenge the industry misalignment of PBMs behind-the-scenes role. Michael Thompson, National Alliance president and CEO, said, "With health plans and PBMs increasingly owning each other and the growing side deal payment arrangements to consultants and brokers, this is a classic case of the 'fox guarding the henhouse'."
To address this, the National Alliance has created a playbook, its resource that examines the role of the fiduciary in pharmacy benefit management and offers insights on the drivers of pharmacy benefit costs and value, and flaws in the contracting and negotiation process. It offers employers or health purchasers access to best practice checklists, sample questionnaires for selecting consultants and recommended contracting language.
The National Alliance maintains some of the concerns surrounding PBM practices include promotion of higher-price drugs when lower-price drugs are available; systematic approaches to encourage waste including refilling too soon or automatic 90-day refill; a narrow definition of "rebates" which allows the PBM to "pocket" 50% or more of the manufacturer revenue because they have been recharacterized as something else, and plan sponsors being "held hostage" on any and all PBM contract terms, financial guarantees, and provisions regardless of magnitude of desired benefit changes.
Reference: Purchaser Coalitions Releases Call to Action for Employers to Address Conflicts in the PBM Industry, Washington, June 26, 2023, PRNewswire.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Roche Inks Deal to Acquire Poseida Therapeutics
December 2nd 2024Under terms of the deal, Roche will gain access to Poseida’s pipeline, including P-BCMA-ALLO1, an allogeneic CAR T-cell therapy for multiple myeloma, and P-CD19CD20-ALLO1, a dual CAR T-cell therapy in early trials for B-cell malignancies and autoimmune diseases.